<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049567</url>
  </required_header>
  <id_info>
    <org_study_id>AIOL-2009-1</org_study_id>
    <nct_id>NCT02049567</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL)</brief_title>
  <official_title>Clinical Evaluation of the FluidVision Accommodating Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PowerVision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PowerVision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an investigational&#xD;
      IOL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will receive the investigational IOL in one eye and be followed at 1 day, 1&#xD;
      week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months and 36 months&#xD;
      post-operation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2014</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">June 24, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accommodative amplitude</measure>
    <time_frame>Month 6</time_frame>
    <description>Accommodative amplitude is a measure of the ability of the eye to focus from a target that is at distance into a target that is near.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected distance visual acuity (BCDVA)</measure>
    <time_frame>Month 6</time_frame>
    <description>Visual acuity of the eye will be tested with the correction in place.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of adverse events</measure>
    <time_frame>Up to Month 36</time_frame>
    <description>Adverse events will be collected from time of enrollment to study exit</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Aphakia</condition>
  <arm_group>
    <arm_group_label>FluidVision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FluidVision AIOL</intervention_name>
    <description>Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject</description>
    <arm_group_label>FluidVision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract Surgery</intervention_name>
    <description>Performed using standard microsurgical techniques</description>
    <arm_group_label>FluidVision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for primary intraocular lens implantation for the correction of aphakia&#xD;
             following cataract extraction;&#xD;
&#xD;
          -  Best corrected distance visual acuity worse than 20/40 either with or without a glare&#xD;
             source present (e.g. Brightness Acuity Tester);&#xD;
&#xD;
          -  Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism;&#xD;
&#xD;
          -  Willing and able to comply with schedule for follow-up visits for 36 months after&#xD;
             surgery.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Systemic disease that could increase the operative risk or confound the outcome (e.g.&#xD;
             autoimmune disease, diabetes);&#xD;
&#xD;
          -  Taking systemic medications that may confound the outcome or increase the risk to the&#xD;
             subject;&#xD;
&#xD;
          -  Ocular conditions that may predispose for future complications;&#xD;
&#xD;
          -  Previous intraocular or corneal surgery that might confound the outcome of the&#xD;
             investigation or increase the risk to the subject;&#xD;
&#xD;
          -  Pregnant, lactating during the course of the investigation, or with another condition&#xD;
             associated with fluctuation of hormones that could lead to refractive changes;&#xD;
&#xD;
          -  Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal&#xD;
             disorders) that are predicted to cause future best corrected visual acuity loss worse&#xD;
             than 20/40.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine-Westphalia</state>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Claremont</city>
        <state>Cape Town</state>
        <zip>7708</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Northcliff</city>
        <state>Johannesburg</state>
        <zip>2195</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Queenswood</city>
        <state>Pretoria</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Paardevlei</city>
        <state>Somerset West</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

